PoggeRC. The toxic placebo. Med Times1963;91:773–8.
2.
BallengerJCMcDonaldSNoyesRRickelsKSussmanNWoodsSThe first double-blind, placebo-controlled trial of a partial benzodiazepine agonist abecarnil (ZK 112–119) in generalized anxiety disorder. Psychopharmacol Bull1991;27:171–9.
3.
DiamondBINguyenHO'NealEOchsRKaffemanMBorisonRL. A comparative study of alpidem, a non-benzodiazepine, and lorazepam in patients with nonpsychotic anxiety. Psychopharmacol Bull1991;27:67–71.
4.
RickelsKDowningRSchweizerEHassmanH. Antidepressants for the treatment of generalized anxiety disorder: A placebo-controlled comparison of imipramine, trazodone, and diazepam. Arch Gen Psychiatry1993;50:884–95.
5.
BorisonRLAlbrechtJWDiamondBI. Efficacy and safety of a putative anxiolytic agent: Ipsapirone. Psychopharmacol Bull1990;26:207–10.
6.
BoyerWFFeighnerJP. A placebo-controlled double-blind multicenter trial of two doses of ipsapirone versus diazepam in generalized anxiety disorder. Int Clin Psychopharmacol1993;8:173–6.
7.
AnsseauMOlieJPFrenckellRJourdainGStehleBGuilletP. Controlled comparison of the efficacy and safety of four doses of suriclone, diazepam, and placebo in generalized anxiety disorder. Psychopharmacology1991;104:439–43.
8.
PiercyMASramekJJKurtzNMCutlerNR. Placebo response in anxiety disorders. Ann Pharmacother1996;30:1013–9.
9.
SramekJJFrackiewiczEJPiercyMAKurtzNMMurphyMFCartaAAdverse events in placebo-treated patients with generalized anxiety disorder (letter). Depression Anxiety1997;5:142–3.
10.
ShapiroAKChassenJMorrisLAFrickR. Placebo induced side effects. J Operational Psychiatry1974;6:43–6.
